NDAOTICSOLUTION/DROPS
Approved
Feb 1978
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 15h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRIDESILON is a fixed-combination otic solution containing glacial acetic acid and desonide, a low-potency corticosteroid, indicated for ear infections and inflammatory conditions of the external auditory canal. The acetic acid provides antimicrobial activity while desonide reduces inflammation. This is a classic topical otic formulation designed for localized ear canal treatment.
LOE Approaching
As a legacy otic product approaching loss of exclusivity, the brand team is likely focused on defending market position and managing decline rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on TRIDESILON offers limited career upside given its LOE-approaching status and lack of active clinical development. Roles are primarily defensive—managing market share, preparing for generic competition, and optimizing existing indication penetration rather than driving innovation.
Brand ManagerProduct Manager
Worked on TRIDESILON at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.